Recover Clones With 99% Monoclonality Assurance And Reduce Timelines

Cell Line Development (CLD) on the Beacon® optofluidic system enables high throughput cloning, screening, and selection of top-performing CHO cell lines in just days. The Opto® CLD workflow has enabled customers to select clones with higher titers than traditional methods, increase throughput by 4X while reducing their cell line development timeline by up to 50%, and recover clones with >99% monoclonality assurance to support FDA IND regulatory filings.

In addition, the Opto™ Assure quality assays enable users to select clones with favorable product quality attributes within 5 days of cloning to reduce overall costs, improve the probability of success, and further shorten timelines by selecting top clones for scale up.

Explore how this optofluidic system from Berkeley Lights offers an integrated end-to-end automated workflow for rapid cloning and selection in mammalian cell line development.